MHC-II molecules, particularly HLA-DRA, are critical for antigen presentation to CD4+ T cell and required for antiPD-1/PD-L1 activity in melanoma; agents that induce MHC-II positivity can be combined with PD-1/PD-L1-targeted therapy to improve response rates [40]. This evidence concerns the gene CD4 and melanoma.